Please login to the form below

Not currently logged in
Email:
Password:

Akinion appoints Dr Richard Jones as CEO

He joins the biotech firm from GlaxoSmithKline

Akinion Dr Richard JonesDr Richard Jones has been appointed as chief executive officer for privately-held Swedish biotech firm Akinion Pharmaceuticals.

He brings more than 20 years of pharmaceutical industry experience to the company and arrives from Novartis where he was vice president, medicines commercialisation leader, haematology, global oncology.

Before that Dr Jones served at GlaxoSmithKline, where he was most recently VP, global haematology medicines commercialisation leader.

In that role he was responsible for delivering the big pharma company's global haematology strategy, and prior to he served at Sanofi Genzyme as director and M&A transition lead for its transplant and oncology global business unit.

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently in a phase I/II clinical trial.

27th January 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics